Detalhe da pesquisa
1.
Kidney function loss and albuminuria progression with GLP-1 receptor agonists versus basal insulin in patients with type 2 diabetes: real-world evidence.
Cardiovasc Diabetol
; 22(1): 126, 2023 05 27.
Artigo
em Inglês
| MEDLINE | ID: mdl-37244998
2.
Curalin supplement for patients with type 2 diabetes mellitus.
Diabetes Metab Res Rev
; 39(4): e3624, 2023 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-36797773
3.
The effect of lifestyle intervention on cardiometabolic risk factors in mental health rehabilitation hostel residents at-risk: a cluster-randomized controlled 15-month trial.
Int J Obes (Lond)
; 46(5): 926-934, 2022 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-35022545
4.
Epidemiology of the diabetes-cardio-renal spectrum: a cross-sectional report of 1.4 million adults.
Cardiovasc Diabetol
; 21(1): 104, 2022 06 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-35689214
5.
Cardiorenal outcomes with sodium/glucose cotransporter-2 inhibitors in patients with type 2 diabetes and low kidney risk: real world evidence.
Cardiovasc Diabetol
; 20(1): 169, 2021 08 18.
Artigo
em Inglês
| MEDLINE | ID: mdl-34407822
6.
Cardiorenal outcomes with dapagliflozin by baseline glucose-lowering agents: Post hoc analyses from DECLARE-TIMI 58.
Diabetes Obes Metab
; 23(1): 29-38, 2021 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-32844557
7.
Cardiovascular and renal benefits of dapagliflozin in patients with short and long-standing type 2 diabetes: Analysis from the DECLARE-TIMI 58 trial.
Diabetes Obes Metab
; 22(7): 1122-1131, 2020 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-32090404
8.
Safety of dapagliflozin in a broad population of patients with type 2 diabetes: Analyses from the DECLARE-TIMI 58 study.
Diabetes Obes Metab
; 22(8): 1357-1368, 2020 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-32239659
9.
Risk of hospitalization with sodium-glucose cotransporter-2 inhibitors versus dipeptidyl peptidase-4 inhibitors in patients with type 2 diabetes lacking evidence of chronic kidney disease: Real-world data.
Diabetes Obes Metab
; 25(10): 3054-3058, 2023 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-37385956
10.
Hypoglycaemia manifestations and recurrent events: Lessons from the SAVOR-TIMI 53 outcome study.
Diabetes Obes Metab
; 19(7): 1045-1050, 2017 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-28181728
11.
Medical cannabis for pain management in patients undergoing chronic hemodialysis: randomized, double-blind, cross-over, feasibility study.
Clin Kidney J
; 16(4): 701-710, 2023 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-37007688
12.
Long-Term, Real-World Kidney Outcomes with SGLT2i versus DPP4i in Type 2 Diabetes without Cardiovascular or Kidney Disease.
Clin J Am Soc Nephrol
; 18(9): 1153-1162, 2023 09 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-37382938
13.
Efficacy and Safety of Dapagliflozin by Baseline Insulin Regimen and Dose: Post Hoc Analyses From DECLARE-TIMI 58.
Diabetes Care
; 46(1): 156-164, 2023 01 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-36399721
14.
Effects of dapagliflozin on hospitalisations in people with type 2 diabetes: post-hoc analyses of the DECLARE-TIMI 58 trial.
Lancet Diabetes Endocrinol
; 11(4): 233-241, 2023 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-36878239
15.
Association of Baseline HbA1c With Cardiovascular and Renal Outcomes: Analyses From DECLARE-TIMI 58.
Diabetes Care
; 45(4): 938-946, 2022 04 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-35015847
16.
Dapagliflozin and Prevention of Kidney Disease Among Patients With Type 2 Diabetes: Post Hoc Analyses From the DECLARE-TIMI 58 Trial.
Diabetes Care
; 45(10): 2350-2359, 2022 10 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-35997319
17.
Cardiovascular, Renal, and Metabolic Outcomes of Dapagliflozin Versus Placebo in a Primary Cardiovascular Prevention Cohort: Analyses From DECLARE-TIMI 58.
Diabetes Care
; 44(5): 1159-1167, 2021 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-33653824
18.
The Effect of Dapagliflozin on Albuminuria in DECLARE-TIMI 58.
Diabetes Care
; 44(8): 1805-1815, 2021 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-34233928
19.
Efficacy and Safety of Dapagliflozin in the Elderly: Analysis From the DECLARE-TIMI 58 Study.
Diabetes Care
; 43(2): 468-475, 2020 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-31843945
20.
Effect of Flash Glucose Monitoring Technology on Glycemic Control and Treatment Satisfaction in Patients With Type 2 Diabetes.
Diabetes Care
; 42(7): 1178-1184, 2019 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-31036546